Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Current Oncology Reports"
DOI: 10.1007/s11912-018-0693-y
Abstract: Purpose of ReviewAdvanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key… read more here.
Keywords: carcinoma; level evidence; platinum refractory; urothelial carcinoma ... See more keywords
Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001450
Abstract: Metastatic urothelial carcinoma (mUC) is associated with poor prognosis. Cisplatin-based combination chemotherapy is the preferred initial regimen for patients with mUC. However, a substantial proportion of patients cannot receive cisplatin-based chemotherapy due to renal impairment… read more here.
Keywords: cisplatin; metastatic urothelial; cisplatin ineligible; tislelizumab ... See more keywords
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Immunotherapy (Hagerstown, Md. : 1997)"
DOI: 10.1097/cji.0000000000000441
Abstract: Immune checkpoint inhibitors (ICIs) are widely used for first-line cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC). However, whether to use ICIs as monotherapy or in combination with chemotherapy is still uncertain. We retrospectively analyzed cisplatin-ineligible… read more here.
Keywords: checkpoint inhibitor; immune checkpoint; cisplatin ineligible; first line ... See more keywords
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4502
Abstract: 4502Background: Comorbidities and renal impairment preclude many with advanced UC from receiving chemotherapy. Initial results from the phase 2 KEYNOTE-052 (NCT02335424) trial suggested first-line pembro is active and safe in cisplatin-ineligible advanced UC. We present… read more here.
Keywords: first line; ineligible advanced; cisplatin; cisplatin ineligible ... See more keywords